ReviewBiomolecules2025
Understanding the Role of Adipokines in Cardiometabolic Dysfunction: A Review of Current Knowledge.
Review in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Exploring the mechanisms of serum miRNA in obesity-related kidney injury.International urology and nephrology · 2026Review
- Review
- Differential Therapeutic Modulations of Adiponectin: Beneficial, Adverse, and Context-Dependent Effects in Chronic Coronary Syndromes.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2026Review
- Clustering adipokines, metabolic, oxidative stress, and inflammatory markers associated with cardiovascular disease risk in patients with metabolic syndrome.Diabetology & metabolic syndrome · 2026Article
- Diagnostic Potential of Metabolomic and Proteomic Biomarkers in Cardiology-A Narrative Review.Biomedicines · 2026Review
- Association of the triglyceride-glucose index with inflammatory markers and dysregulation of adipokines in patients with metabolic syndrome.BMC endocrine disorders · 2026Article
- The Adipokine Axis in Heart Failure: Linking Obesity, Sarcopenia and Cardiac Dysfunction in HFpEF.International journal of molecular sciences · 2026Review
- C1q/TNF-Related Protein 4 (C1QTNF4) Acts as an Adipokine That Ameliorates Diet-Induced Obesity by Improving Energy Metabolism and Alleviating Adipose Inflammation.Mediators of inflammation · 2026Article
- Determinants of inflammatory and adipokine biomarkers in obese young women: The role of skeletal muscle and lifestyle factors in Indonesia.Journal of education and health promotion · 2026Article
- Lycopene's Role in Mitigating Obesity-Induced Cardiac Remodeling: Insights Into Inflammatory and MMP-2 Pathways.Molecular nutrition & food research · 2026Article
- Article
- The nonlinear association between Body Roundness Index and left ventricular diastolic dysfunction in type 2 diabetes.Frontiers in endocrinology · 2026Article
- Fatty acid binding protein 4 as a diagnostic biomarker for peripheral arterial disease in type 2 diabetes: a cross-sectional study.BMC cardiovascular disorders · 2025Observational
- Endothelial Dysfunction as the Common Pathway Linking Obesity, Hypertension and Atherosclerosis.International journal of molecular sciences · 2025Review
- Overlapping risk factors and pathogenic mechanisms in lung cancer and cardiovascular disease.Discover oncology · 2025Review
- The Visceral Adiposity Index and Its Usefulness in the Prediction of Cardiometabolic Disorders.Nutrients · 2025Review
- What role will physiological resilience play in brown-white fat dynamic in obesity management?Frontiers in pharmacology · 2025Article
- Gut mycobiome in cardiometabolic disease progression: current evidence and future directions.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Cardiometabolic risk and associated dysfunctions contribute largely to the recent rise in mortality globally. Advancements in multi-omics in recent years promise a better understanding of potential biomarkers that enable an early diagnosis of cardiometabolic dysfunction. However, the molecular mechanisms driving the onset and progression of cardiometabolic disorders remain poorly understood. Adipokines are adipocyte-specific cytokines that are central to deleterious cardiometabolic alterations. They exhibit both pro-inflammatory and anti-inflammatory effects, complicating their association with cardiometabolic disturbances. Thus, understanding the cardiometabolic association of adipokines from a molecular and signaling perspective assumes great importance. This review presents a comprehensive outline of the most prominent adipokines exhibiting pro-inflammatory and/or anti-inflammatory functions in cardiometabolic dysfunction. The review also presents an insight into the pathophysiological implications of such adipokines in different cardiometabolic dysfunction conditions, the status of adipokine druggability, and future studies that can be undertaken to address the existing scientific gap. A clear understanding of the functional and mechanistic role of adipokines can potentially improve our understanding of cardiovascular disease pathophysiology and enhance our current therapeutic regimen in the years to come.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.